VHL GENE INACTIVATION

Clinical trials for VHL GENE INACTIVATION explained in plain language.

Never miss a new study

Get alerted when new VHL GENE INACTIVATION trials appear

Sign up with your email to follow new studies for VHL GENE INACTIVATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New pill shrinks kidney tumors in rare genetic disease

Disease control Ongoing

This study tests a drug called belzutifan for people with von Hippel-Lindau (VHL) disease who have kidney cancer. The goal is to see if the drug can shrink kidney tumors and avoid surgery. About 50 adults with VHL and at least one measurable kidney tumor will take the pill and be…

Matched conditions: VHL GENE INACTIVATION

Phase: PHASE2 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control

Last updated Jun 05, 2026 12:06 UTC

VHL GENE INACTIVATION

Get alerted when new VHL GENE INACTIVATION trials appear

New pill shrinks kidney tumors in rare genetic disease